Moderna has outlicensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.

Moderna, Inc. stock is up ~60% YTD on cancer vaccine trial data, 2026 readouts, and 2025 financials. Click for this updated ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a Buy.

BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the ...

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

Dr Melanie Ivarsson was on Monday named chief executive of the Health Data Research Service (HDRS), which will give researchers a single access point to NHS datasets.

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. | Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after ...